US-based AI company Anumana has revealed results from a study of an algorithm based on electrocardiogram (ECG) designed to recognise signs of pulmonary hypertension (PH) to expedite diagnosis.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an ...
CAMBRIDGE, Mass., March 28, 2026--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) ...
Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device ...
Anumana has received 510(k) clearance from the US Food and Drug Administration (FDA) for its ECG-AI pulmonary hypertension (PH) detection algorithm, a software-as-a-medical-device (SaMD). The ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する